X4 Pharmaceuticals XFOR Stock
X4 Pharmaceuticals Price Chart
X4 Pharmaceuticals XFOR Financial and Trading Overview
| X4 Pharmaceuticals stock price | 3.5 USD |
| Previous Close | 3.4 USD |
| Open | 3.44 USD |
| Bid | 2.47 USD x 200 |
| Ask | 4.39 USD x 200 |
| Day's Range | 3.24 - 3.55 USD |
| 52 Week Range | 2.8 - 4.83 USD |
| Volume | 1.25M USD |
| Avg. Volume | 847.16K USD |
| Market Cap | 347.01M USD |
| Beta (5Y Monthly) | 0.395 |
| PE Ratio (TTM) | 2.4475524 |
| EPS (TTM) | 1.43 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.6 USD |
XFOR Valuation Measures
| Enterprise Value | 206.35M USD |
| Trailing P/E | 2.4475524 |
| Forward P/E | -4.560261 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 21.897747 |
| Price/Book (mrq) | 2.1645021 |
| Enterprise Value/Revenue | 13.022 |
| Enterprise Value/EBITDA | -2.612 |
Trading Information
X4 Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.395 |
| 52-Week Change | 4.29% |
| S&P500 52-Week Change | 15.30% |
| 52 Week High | 4.83 USD |
| 52 Week Low | 2.8 USD |
| 50-Day Moving Average | 4.03 USD |
| 200-Day Moving Average | 3.94 USD |
XFOR Share Statistics
| Avg. Volume (3 month) | 847.16K USD |
| Avg. Daily Volume (10-Days) | 863.64K USD |
| Shares Outstanding | 99.15M |
| Float | 62.8M |
| Short Ratio | 10.69 |
| % Held by Insiders | 0.44% |
| % Held by Institutions | 100.13% |
| Shares Short | 7.19M |
| Short % of Float | 7.27% |
| Short % of Shares Outstanding | 7.24% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -186.13% |
| Gross Margin | 81.51% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.14% |
| Return on Equity (ttm) | -113.078% |
Income Statement
| Revenue (ttm) | 15.85M USD |
| Revenue Per Share (ttm) | 0.16 USD |
| Quarterly Revenue Growth (yoy) | 346.30% |
| Gross Profit (ttm) | 12.92M USD |
| EBITDA | -79004000 USD |
| Net Income Avi to Common (ttm) | -90138000 USD |
| Diluted EPS (ttm) | 1.43 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 207.97M USD |
| Total Cash Per Share (mrq) | 2.1 USD |
| Total Debt (mrq) | 77.22M USD |
| Total Debt/Equity (mrq) | 49.68 USD |
| Current Ratio (mrq) | 11.301 |
| Book Value Per Share (mrq) | 1.617 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -83736000 USD |
| Levered Free Cash Flow (ttm) | -53310876 USD |
Profile of X4 Pharmaceuticals
| Country | United States |
| State | MA |
| City | Boston |
| Address | 61 North Beacon Street |
| ZIP | 02134 |
| Phone | 857 529 8300 |
| Website | https://www.x4pharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 45 |
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Q&A For X4 Pharmaceuticals Stock
What is a current XFOR stock price?
X4 Pharmaceuticals XFOR stock price today per share is 3.5 USD.
How to purchase X4 Pharmaceuticals stock?
You can buy XFOR shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for X4 Pharmaceuticals?
The stock symbol or ticker of X4 Pharmaceuticals is XFOR.
Which industry does the X4 Pharmaceuticals company belong to?
The X4 Pharmaceuticals industry is Biotechnology.
How many shares does X4 Pharmaceuticals have in circulation?
The max supply of X4 Pharmaceuticals shares is 99.15M.
What is X4 Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
X4 Pharmaceuticals PE Ratio is 2.44755240 now.
What was X4 Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
X4 Pharmaceuticals EPS is 1.43 USD over the trailing 12 months.
Which sector does the X4 Pharmaceuticals company belong to?
The X4 Pharmaceuticals sector is Healthcare.
X4 Pharmaceuticals XFOR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26333.04 USD — |
+0.96
|
5.66B USD — | 26283.11 USD — | 26431.22 USD — | — - | 5.66B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
137.24 USD — |
+0.22
|
— — | 137.22 USD — | 139.48 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1293.65 USD — |
+0.08
|
— — | 1293.64 USD — | 1310.12 USD — | — - | — — |
- {{ link.label }} {{link}}
